The Psychological and Social Burden of Psoriasis

Psoriasis exerts a psychological toll that is frequently disproportionate to the physical severity of the disease. A patient with limited disease on the hands, face, or genitals may experience greater psychological distress than a patient with extensive disease on the trunk and limbs. Understanding the mental health dimensions of psoriasis is essential for holistic care.

16.1 Depression

Depression is the most-studied psychiatric comorbidity in psoriasis. A landmark UK population-based cohort study (n = 146,042 psoriasis patients vs. 766,950 controls) found adjusted hazard ratios for depression of 1.39 overall (95% CI 1.37–1.41), rising to 1.72 for severe psoriasis (95% CI 1.57–1.88). The authors estimated that, in the UK alone, over 10,400 diagnoses of depression per year are attributable to psoriasis (Kurd et al., 2010). A systematic review and meta-analysis found that approximately 28% of psoriasis patients report depressive symptoms on screening questionnaires, and 12–19% meet formal clinical diagnostic criteria for depression (Dowlatshahi et al., 2014). Depression is more prevalent among women with psoriasis and among those with more severe disease, psoriatic arthritis, or multiple comorbidities.

The relationship is likely bidirectional. Psoriasis causes depression through psychological and social mechanisms: stigma, shame, restricted activities, relationship difficulties, reduced employment. But depression may also worsen psoriasis through biological pathways. Proinflammatory cytokines elevated in psoriasis, including IL-1, IL-6, and IL-17, are also elevated in major depressive disorder, suggesting shared inflammatory mechanisms. In a secondary analysis of two large RCTs, ixekizumab (an anti-IL-17A antibody) produced both depression remission and reduction in serum CRP in patients with comorbid psoriasis and moderate-to-severe depression, supporting a neuroinflammatory link (Griffiths et al., 2017).

16.2 Suicidal Ideation and Suicide

The relationship between psoriasis and suicidality has been examined in multiple systematic reviews with somewhat conflicting results. The UK cohort study above found an adjusted hazard ratio for suicidality of 1.44 (95% CI 1.32–1.57). A well-controlled pan-European study of 3,635 dermatological patients across 13 countries (including a psoriasis subgroup) reported an approximately twofold greater risk of suicidal ideation compared to controls (adjusted OR 1.94, 95% CI 1.33–2.82) (Dalgard et al., 2015). Among tertiary patients with moderate-to-severe disease, up to 49% report lifetime suicidal thoughts (Lada et al., 2022).

The 2025 BADBIR analysis (British Association of Dermatologists Biologics and Immunomodulators Register) specifically examined suicide risk in patients with clinically confirmed moderate-to-severe psoriasis (Williams et al., 2025). Patients with a history of psychiatric comorbidity had significantly increased rates of all suicidality outcomes. However, the overall suicide rate among psoriasis patients was not significantly elevated compared to the general population. The authors emphasised the high prevalence of undiagnosed depression and the need for routine mental health assessment at every dermatology appointment.

16.3 Anxiety Disorders

Anxiety has received less attention than depression in psoriasis research, but it may be even more prevalent. A systematic review of observational studies found elevated rates of anxiety in psoriasis patients, with prevalence estimates varying widely across studies depending on assessment method and population (Fleming et al., 2017). The most common presentations include generalised anxiety disorder, social anxiety disorder, and health anxiety.

Social anxiety is particularly relevant. The visibility of psoriasis creates a specific type of anticipatory dread: worry about being stared at, asked intrusive questions, or rejected. Patients with psoriasis on visible sites (hands, face, scalp) report higher anxiety than those with trunk-limited disease, regardless of total BSA. Social anxiety drives avoidance behaviours (declining invitations, changing clothing choices, avoiding intimacy) that compound the quality-of-life burden.

Health anxiety in psoriasis takes several forms: fear of disease progression, worry about medication side effects, and anxiety about passing the condition to children. These concerns aren’t irrational given psoriasis’s chronic nature and real comorbidity burden (Section 14), but when they become disproportionate and disabling, they warrant treatment.

The bidirectional relationship between anxiety and psoriasis mirrors that of depression: anxiety triggers the stress-inflammation axis (Section 8.3), which can worsen skin disease, which in turn worsens anxiety. Clinicians should screen for anxiety alongside depression, using validated tools such as the GAD-7.

The Brodalumab Suicidality Signal

Brodalumab (Siliq), an IL-17 receptor blocker, carries a boxed warning for suicidal ideation and behaviour. This stems from four completed suicides during its clinical trial programme (three in the psoriasis trials, one in the PsA trial). The context matters, though. All four individuals had pre-existing psychiatric comorbidities. Post-marketing surveillance and large cohort analyses haven’t confirmed a causal link between brodalumab and suicidality beyond what would be expected in a severe psoriasis population with high baseline psychiatric comorbidity (Lebwohl et al., 2021). A pooled safety analysis of over 2,600 brodalumab-treated patients found suicide rates consistent with those in the general psoriasis population.

The practical consequence is that brodalumab requires a Risk Evaluation and Mitigation Strategy (REMS) programme in the US, limiting its prescribing to certified healthcare settings. Whether the boxed warning reflects a true drug effect or the background psychiatric burden of severe psoriasis remains debated. What’s not debated: any patient starting systemic psoriasis therapy should be screened for depression and suicidal ideation, regardless of which drug they’re prescribed.

Unlike many chronic diseases, psoriasis is visible. Patients report being stared at, refused service at hairdressers and swimming pools, asked whether their condition is contagious, and experiencing rejection in intimate relationships. A concept termed “social skin” has been used in the dermatology literature to describe how the skin mediates social identity and interpersonal connection, and how visible skin disease disrupts this.

The WHO’s 2016 Global Report on Psoriasis highlighted that patients frequently feel humiliated, stigmatised, and socially excluded, and called on governments to recognise psoriasis as a serious non-communicable disease. The report noted that patients with psoriasis often change their behaviour to avoid situations where their skin might be visible: avoiding swimming, changing how they dress, declining social invitations, and withdrawing from sexual relationships.

16.5 Impact on Employment and Productivity

Psoriasis significantly affects working life. Studies using the Work Productivity and Activity Impairment (WPAI) questionnaire have documented that patients with moderate-to-severe psoriasis experience substantial work impairment, with total productivity losses of 19–29% of working time depending on disease severity. That’s equivalent to approximately one to two lost working days per week (Korman et al., 2016). Career limitation is common: patients report avoiding certain professions, declining promotions that involve public visibility, and taking early retirement.

Hand psoriasis and occupational challenges. Psoriasis affecting the hands is particularly disabling for employment. Manual workers, healthcare professionals, food handlers, and those in any occupation requiring frequent hand washing or wet work face both functional impairment (painful cracking, reduced grip strength) and social barriers (colleagues’ and customers’ reactions to visible lesions). Occupational dermatology services can provide workplace assessments and recommendations.

Occupation-specific challenges. Some jobs create particular difficulties:

Healthcare workers: Hand psoriasis conflicts directly with infection control requirements. Frequent handwashing and alcohol gel worsen fissuring and pain, while visible lesions can trigger patient concerns. Emollient-friendly hand hygiene protocols and barrier creams applied before shifts can help. Occupational health teams can provide documentation confirming psoriasis is non-infectious.
Food handlers: Food safety regulations in many countries require that skin lesions be covered or that affected workers be temporarily reassigned from food-contact roles. Psoriasis isn’t an infection risk, but explaining this to managers unfamiliar with the condition can be frustrating. A letter from your dermatologist clarifying that psoriasis is non-contagious and poses no food safety risk is useful.
Wet-work occupations (hairdressers, cleaners, bar staff): Prolonged water and detergent exposure damages the skin barrier and worsens psoriasis. Barrier creams, cotton-lined gloves, and emollient substitutes for soap are essential.
Manual labourers and tradespeople: Friction, pressure, and repeated minor trauma trigger the Koebner phenomenon (Section 8.9). Padded gloves, knee pads, and avoidance of tight-fitting safety equipment where possible can reduce flares at friction sites.

Legal protections. In the UK, psoriasis can qualify as a disability under the Equality Act 2010 if it has a “substantial and long-term adverse effect” on a person’s ability to carry out normal day-to-day activities. In the US, severe psoriasis may be covered under the Americans with Disabilities Act (ADA). Reasonable workplace adjustments may include flexible working arrangements, access to private changing facilities, modified dress codes, and time off for treatment appointments.

Employer communication. Patients often struggle with whether and how to disclose their condition to employers. Advocacy organisations (Appendix A2) provide template letters and guidance for workplace conversations. Where possible, involving the occupational health department can facilitate appropriate adjustments without requiring the patient to disclose details to managers or colleagues directly.

16.6 Impact on Partners, Families, and Caregivers

Psoriasis doesn’t affect just the person who has it. Partners, parents, and family members carry a burden that’s rarely measured and almost never addressed in clinical consultations.

Partners of people with psoriasis report elevated anxiety, relationship strain, and reduced sexual satisfaction, often independent of the patient’s actual disease severity (Eghlileb et al., 2007). The daily routines of emollient application, scale management, and laundry (emollients stain sheets and clothing) affect the entire household. Partners may take on a caregiving role, helping apply treatments to hard-to-reach areas like the back or scalp, while simultaneously navigating the emotional distance that shame and self-consciousness can create.

Parents of children with psoriasis face particular challenges. Managing a child’s treatment regimen, dealing with school bullying, explaining the condition to other parents, and coping with the distress of watching a child in pain or embarrassment all take a toll. Maternal anxiety is common, especially in mothers who also have psoriasis and feel responsible for passing it on.

The Family Dermatology Life Quality Index (FDLQI) was developed to measure this impact, covering emotional distress, daily activities, relationships, and the time and financial burden of supporting someone with a skin condition (Basra et al., 2007). Studies using the FDLQI consistently find that family members’ quality of life correlates with the patient’s DLQI score but isn’t fully explained by it. In other words, family burden exists even when patients themselves report manageable disease.

What helps? Including partners in consultations (with the patient’s consent), explaining the treatment plan so the whole household understands it, and acknowledging that living with someone who has psoriasis is genuinely difficult. Patient organisations (Appendix A2) often run partner and family support groups. For parents of children with psoriasis, connecting with other families through organisations like the Psoriasis Association can reduce the isolation.

16.7 Psychological Interventions

Growing evidence supports incorporating psychological support into psoriasis care. Cognitive behavioural therapy (CBT), mindfulness-based stress reduction (MBSR), and habit reversal training (for itch-scratch cycles) have all shown benefit in small trials. One landmark early study found that psoriasis patients who listened to mindfulness meditation tapes during phototherapy sessions achieved skin clearing significantly faster than those receiving phototherapy alone (Kabat-Zinn et al., 1998). Current guidelines increasingly advocate routine mental health screening, using validated tools such as the PHQ-2 or PHQ-9 for depression and asking about suicidal ideation, at every dermatology appointment, particularly when starting, changing, or reviewing systemic treatment.